Overview

Pharmacokinetic and Safety Study of Nab®-Paclitaxel (ABI-007) Plus Gemcitabine in Subjects With Advanced Pancreatic Cancer Who Have Cholestatic Hyperbilirubinemia

Status:
Terminated

Trial end date:
2016-02-10

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine the safety and pharmacokinetic profile of nab®-paclitaxel (ABI-007) plus gemcitabine in subjects with advanced pancreatic cancer who have cholestatic hyperbilirubinemia secondary to bile duct obstruction.

Phase:

Phase 1

Details

Lead Sponsor:

Celgene
Celgene Corporation

Treatments:

Albumin-Bound Paclitaxel
Bilirubin
Gemcitabine
Paclitaxel